Agostinho João Almeida — investor profile photo

Agostinho João Almeida

Corporate Venturing | Impact | Innovation | R&D

📍 Colombia, Colombia🔄 Updated November 2026💼 4 investments📅 14 years investing🗓 Last invested May 2018𝕏 @upgrade_to_unlock
VC🌍 Colombia
4
Total investments
0
Early stage
1
Mid stage
0
Late stage
14y
Years active

Portfolio

1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
May 2015
Brainz is a next-generation entertainment company focusing on developing original, story-driven IPs through mobile games with superb production values. Its first title, Vampire Season-Monster Defense was released in the summer of 2012 to critical acclaim globally. Brainz is part of ZIO, one of Latin America’s top 3D animation and digital media studios with staff of 30+ in Bogota, Colombia. The company has received US$2.1M in angel and VC funding.
Experience · 9 entries
All (9)
Investments (4)
Founder (3)
Board (4)
2018
Digital Americas Pipeline Initiative (DAPI)
Board Member
May 2018
2016
MyEcohome
Board Member
Sep 2016
2015
Board Member
May 2015
Brainz is a next-generation entertainment company focusing on developing original, story-driven IPs through mobile games with superb production values. Its first title, Vampire Season-Monster Defense was released in the summer of 2012 to critical acclaim globally. Brainz is part of ZIO, one of Latin America’s top 3D animation and digital media studios with staff of 30+ in Bogota, Colombia. The company has received US$2.1M in angel and VC funding.
2014
Investment Manager, Venture Capital
Apr 2014
Promotora is a leading Venture Capital and Private Equity fund manager, as well as an investment banking consulting firm for Latin American small and midsize enterprises. Promotora es una firma especializada en Gestión de Fondos de Capital Privado y Banca de Inversión.
2013
Cofounder
Oct 2013
Immunethep is a biotech startup company (spin-off from the University of Porto) that is developing anti-bacterial immunotherapies based on the discovery of a virulence mechanism shared by different bacteria that cause life-threatening infections. We are working on preventing and treating infectious diseases to improve global health (SDG#3) for a safer tomorrow free of AntiMicrobial Resistance (AMR). We will accomplish our mission by developing anti-infective immunotherapies that potentiate a natural and strong immune response from the infected host, reducing the disease burden and mortality rates.
Show all 9 entries ↓
Investment activity
2012–2018 · 4 investments
20121201512016120181
Recent (last 2 years)Earlier